Shareholders meeting

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/TG/2026-27/41 July 15, 2026 To, To, The Manager The Manager BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code – 532523 Scrip Symbol – Biocon Dear Sir/Madam, Subject: Notice of the 48th Annual General Meeting and Integrated Annual Report for the Financial Year 2025-26 This is further to our letter dated May 07, 2026, intimating that the 48th Annual General Meeting (‘AGM’) of the Company will be held on Thursday August 06, 2026 at 3:30 P.M. (IST) through Video Conferencing (‘VC’) / Other Audio Visual Means (‘OAVM’) in compliance with applicable provisions of the Companies Act, 2013 (‘the Act’) and rules made thereunder, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) read with all applicable circulars on the matter issued by the Ministry of Corporate Affairs (‘MCA’) and the Securities and Exchange Board of India (‘SEBI’). Pursuant to the provisions of Regulation 30 and 34 of the SEBI Listing Regulations, please find enclosed the Notice of 48th AGM and Integrated Annual Report (BRSR, GRI & ESG Data Book FY 26 is a supplement to the Integrated Annual Report) of the Company for the Financial Year 2025-26. The same are also made available on the website of the Company at www.biocon.com. In compliance with the applicable Circulars issued by MCA and SEBI Listing Regulations, the Notice of the 48th AGM along with the Integrated Annual Report for the Financial Year 2025-26 are being sent only through electronic mode to those Members whose e-mail IDs are registered with the Registrar and Share Transfer Agents (‘RTA’) (in case of shares held in physical form) or with Depository Participants (‘DPs’) (in case of shares held in demat form). Further, pursuant to Regulation 36(1)(b) of SEBI Listing Regulations, the Company has also sent letter containing the web- link along with the path and QR Code to access the Notice of the 48th AGM and Integrated Annual Report of the Company for Financial Year 2025-2026, to those Members who have not registered their e-mail IDs with the RTA or with the DPs. Copy of the said letter is enclosed herewith. Request you to kindly take the above intimation on record. Thanking You, Yours faithfully, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance Officer ICSI Membership Number: A16328 Enclosed: Information at a Glance, Integrated Annual Report (BRSR, GRI & ESG Data Book FY 26 being supplement to the Integrated Annual Report), 48th AGM Notice and Letter sent to Members pursuant to Regulation 36(1)(b) of SEBI Listing Regulations. 48th Annual General Meeting of Biocon Limited - Information at a Glance S. No. Particulars Details 1 Day, Date and Time of the AGM Thursday, August 06, 2026 at 3:30 PM (IST) 2 Mode Video Conference (‘VC’) and Other Audio-Visual Means (‘OAVM’) 3 Link for participating in the AGM through https://emeetings.kfintech.com/ VC/OAVM 4 Helpline number for VC participation and 1800-309-4001 & 040-6716 2222 e-voting 5 Email IDs for any assistance or support einward.ris@kfintech.com, evoting@kfintech.com for VC participation and e-voting 6 Cut-off date for e-voting Thursday, July 30, 2026 7 E-voting start time and date 9:00 AM (IST) on Saturday, August 01, 2026 8 E-voting end time and date 5:00 PM (IST) on Wednesday, August 05, 2026 9 E-Voting website https://evoting.kfintech.com/ 10 Speaker Registration for AGM Please visit https://emeetings.kfintech.com and click on ‘Speaker Registration’. The registration will remain open only during the remote e-voting period 11 Record date for Final dividend for Friday, July 03, 2026 Financial Year 2025-26 12 Payment date for Final dividend for On or before Thursday, August 20, 2026 Financial Year 2025-26 13 Registrar and Share Transfer Agent D Suresh Babu (‘RTA’) contact details (Unit: Biocon Limited) KFin Technologies Limited, Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad - 500 032 Integrated Annual Report FY 2026 SCIENCE FOR PEOPLE ADVANCING IMPACT SCIENCE FOR PEOPLE ADVANCING IMPACT At Biocon, we have always believed that science must serve a larger purpose. Scientific discovery is important, but discovery alone is never enough. The true value of science lies in its ability to address human needs, improve lives, and create equitable access to innovation. In healthcare, success cannot be measured solely by scientific breakthroughs. It must be measured by the difference those breakthroughs make in the lives of patients and communities around the world. This belief has guided Biocon from the very beginning. Over the decades, we have focused our efforts on some of the world’s most pressing healthcare challenges – diabetes, cancer, autoimmune diseases and other chronic conditions that place an enormous burden on patients, families and healthcare systems. Our goal has been innovation with purpose: making advanced therapies accessible, affordable and available to those who need them the most. Many of our achievements reflect this commitment. We commercialized India’s first recombinant human insulin developed using our proprietary Pichia pastoris technology. We introduced the world’s first biosimilar Trastuzumab, expanding access to an advanced breast cancer therapy. We became the first company to secure interchangeable biosimilar status in the United States for Insulin Glargine, followed by Insulin Aspart. Our Made-in-India Insulin Glargine reached patients in Japan. We secured the first approval for generic Liraglutide in the UK. These milestones are more than scientific firsts. They represent opportunities created for patients who might otherwise have been denied access to life-changing therapies. Achieving this requires much more than scientific excellence. It requires clarity of purpose, the courage to challenge convention, the discipline to focus on unmet needs, and the ability to translate complex science into high-quality, scalable and affordable solutions. It also demands a deep commitment to manufacturing excellence and global delivery, ensuring that innovation reaches patients wherever they are. As healthcare systems worldwide grapple with the growing burden of chronic diseases, rising costs and persistent inequalities in access, the need for purposeful innovation has never been greater. The future will not belong solely to those who pioneer scientific breakthroughs. It will belong to those who can ensure that such breakthroughs reach millions of people reliably, affordably and at scale. That has been Biocon’s mission for nearly five decades. And it remains our guiding purpose today. Financial Biosimilars:D 104,312 million, (USD 1.18 billion) Highlights Growth 16% Generics:D 31,681 million, FY Total (USD 359 million) income Growth 17% 172,695 million, CRDMO:D 37,387 million, (USD 1.96 billion) (USD 423 million) Growth 14% Growth 3% EBITDA:D 37,978 million, (USD 430 million) AT A G L A N C E Growth 25% EBITDA margin:22% Gross R&D investment:D 9,821 million, (USD 111 million) Profit for the year**:D 3,856 million, (USD 44 million) EPS:D 2.82 Note: Growth calculated on a like-to-like basis after adjusting for upsides from generic Lenalidomide exclusivity sales and divestment of Branded Formulations India business in FY25 ** Profit attributable to shareholders of the Company Generics Business Biosimilars Revenue Contribution CRDMO 02 Biocon Limited Integrated Annual Report FY 2026 NON-FINANCIAL HIGHLIGHTS Environmental Social Governance 258,420 tCO e 9,725 33% Total GHG emission Employees Board diversity – Women reduction (Scope 1&2) on Board 73%* 100% Women representation Re [Showing first 8,000 characters — download PDF for full document]